We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) to Launch Academic R&D Grants With New Pact
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) recently partnered with Thurgood Marshall College Fund (TMCF) to launch the Research & Development Engagement program. The grants will aid innovation, ideas, and solutions in STEM, medical technology, and business research at select Historically Black Colleges and Universities (HBCUs).
Since 2020, Medtronic plc and TMCF have collaborated to create a scholarship program funded by the Medtronic Foundation and an annual internship program across the United States.
More on the News
The funds result from a collaborative relationship between Medtronic and TMCF to foster diversity in STEM education and career development.
In particular, the R&D Engagement Programme, TMCF and Medtronic plc teamed up to give five grants of $40,000 each to professors at TMCF member institutions.
The grant will emphasize that students studying business, medical technology, or other STEM fields will benefit specifically from innovative academic support. Improved academic innovation on campus and/or in the community will support sufficient funding for the conclusion of ground-breaking research and development in STEM, medical technology, and/or business.
Significance of the Grants
The Research & Development Engagement Programme is a paradigm-shifting initiative. The partnership will give teachers access to opportunities to improve their skill set, which affects students and boosts their opportunities to pursue STEM careers in corporate America.
Image Source: Zacks Investment Research
Supporting HBCUs through the R&D Engagement Programme increases possibilities for students from diverse backgrounds and promotes skill development. As part of its dedication to removing all barriers to equity, Medtronic is pleased to collaborate with TMCF on this vital program.
Through this partnership, Medtronic remains committed to delivering the best possible experiences for patients and physicians, expanding healthcare access and delivering positive outcomes. The latest grant plays a massive role in creating some of the world's most meaningful healthcare innovations and improving the lives of millions of people.
Medtronic’s Progress Within R&D Program
In June 2023, Medtronic and Kings College Hospital were given £2.5 million in government funding for a large-scale, real-world trial of GI Genius in NHS hospitals across the UK. The cutting-edge device uses Artificial Intelligence (AI) to assist physicians in detecting colorectal abnormalities such as polyps and gut adenomas, which may progress to cancer.
Earlier this year, Medtronic joined 4,600+ organizations globally that are leading the challenge to become carbon neutral by setting ambitious emissions reduction targets grounded in climate science through the Science Based Targets initiative (SBTi). The SBTi is a collaboration between CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the World Wildlife Fund for Nature (WWF).
Price Performance
In the past year, MDT shares have declined 1.5% compared with the industry’s fall of 9.4%.
Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Quanterix (QTRX - Free Report) , Align Technology (ALGN - Free Report) , each carrying a Zacks Rank #2 (Buy).
DaVita has gained 25.5% against the industry’s 8.9% decline over the past year.
Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 141.5% in the past year compared with the industry’s fall of 5.6%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 27% in the past year compared with the industry’s rise of 14.3%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic (MDT) to Launch Academic R&D Grants With New Pact
Medtronic plc (MDT - Free Report) recently partnered with Thurgood Marshall College Fund (TMCF) to launch the Research & Development Engagement program. The grants will aid innovation, ideas, and solutions in STEM, medical technology, and business research at select Historically Black Colleges and Universities (HBCUs).
Since 2020, Medtronic plc and TMCF have collaborated to create a scholarship program funded by the Medtronic Foundation and an annual internship program across the United States.
More on the News
The funds result from a collaborative relationship between Medtronic and TMCF to foster diversity in STEM education and career development.
In particular, the R&D Engagement Programme, TMCF and Medtronic plc teamed up to give five grants of $40,000 each to professors at TMCF member institutions.
The grant will emphasize that students studying business, medical technology, or other STEM fields will benefit specifically from innovative academic support. Improved academic innovation on campus and/or in the community will support sufficient funding for the conclusion of ground-breaking research and development in STEM, medical technology, and/or business.
Significance of the Grants
The Research & Development Engagement Programme is a paradigm-shifting initiative. The partnership will give teachers access to opportunities to improve their skill set, which affects students and boosts their opportunities to pursue STEM careers in corporate America.
Image Source: Zacks Investment Research
Supporting HBCUs through the R&D Engagement Programme increases possibilities for students from diverse backgrounds and promotes skill development. As part of its dedication to removing all barriers to equity, Medtronic is pleased to collaborate with TMCF on this vital program.
Through this partnership, Medtronic remains committed to delivering the best possible experiences for patients and physicians, expanding healthcare access and delivering positive outcomes. The latest grant plays a massive role in creating some of the world's most meaningful healthcare innovations and improving the lives of millions of people.
Medtronic’s Progress Within R&D Program
In June 2023, Medtronic and Kings College Hospital were given £2.5 million in government funding for a large-scale, real-world trial of GI Genius in NHS hospitals across the UK. The cutting-edge device uses Artificial Intelligence (AI) to assist physicians in detecting colorectal abnormalities such as polyps and gut adenomas, which may progress to cancer.
Earlier this year, Medtronic joined 4,600+ organizations globally that are leading the challenge to become carbon neutral by setting ambitious emissions reduction targets grounded in climate science through the Science Based Targets initiative (SBTi). The SBTi is a collaboration between CDP, the United Nations Global Compact, the World Resources Institute (WRI), and the World Wildlife Fund for Nature (WWF).
Price Performance
In the past year, MDT shares have declined 1.5% compared with the industry’s fall of 9.4%.
Zacks Rank and Key Picks
Medtronic currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Quanterix (QTRX - Free Report) , Align Technology (ALGN - Free Report) , each carrying a Zacks Rank #2 (Buy).
DaVita has an estimated long-term growth rate of 12.7%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita has gained 25.5% against the industry’s 8.9% decline over the past year.
Estimates for Quanterix’s 2023 loss per share have remained constant at 97 cents in the past 30 days. Shares of the company have surged 141.5% in the past year compared with the industry’s fall of 5.6%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for Align Technology’s 2023 earnings have moved up from $8.77 to $8.78 per share in the past 30 days. Shares of the company have increased 27% in the past year compared with the industry’s rise of 14.3%.
ALGN’s earnings beat estimates in three of the trailing four quarters and missed in one. In the last reported quarter, it posted an earnings surprise of 9.90%.